OpenEvidence, a Miami-based AI search engine for doctors, has raised $250 million in a new funding round led by Andreessen Horowitz and hospital systems, valuing the company at $15 billion. This marks the startup's third major funding round in under a year, with total disclosed funding now exceeding $1 billion. The rapid capital influx underscores growing investor confidence in AI tools designed specifically for healthcare professionals.

The company's meteoric rise reflects a broader shift in how venture capital is approaching artificial intelligence. Rather than betting exclusively on foundational AI models or infrastructure, investors are increasingly backing specialized applications that solve real problems for specific industries. OpenEvidence's positioning as a free, ad-supported clinical search tool used directly by physicians at the point of care has resonated with both financial investors and healthcare institutions themselves.

Why Are Hospital Systems Investing Directly in OpenEvidence?

The composition of this funding round is unusual and revealing. Hospital systems are not simply licensing OpenEvidence's product; they are investing capital alongside Andreessen Horowitz and other institutional investors. This customer-investor structure can accelerate adoption faster than a traditional financial round, but it also raises important questions about conflicts of interest. When the same organizations evaluating a clinical tool are also on its cap table, independent validation of the product's accuracy claims becomes harder to verify.

OpenEvidence claims that more than two-thirds of U.S. doctors rely on its AI product for diagnostic and treatment advice, positioning it as "the fastest-growing application for physicians in history." The company integrates with tools from Google and Microsoft, and Anthropic announced a partnership with OpenEvidence this week. Nvidia is also an investor in the startup.

How Does OpenEvidence Compete in the Healthcare AI Market?

• Differentiation Strategy: OpenEvidence positions itself as a free, ad-supported layer physicians use at the point of care, rather than a subscription-based research tool like UpToDate, which is owned by Wolters Kluwer.
• Adoption Speed: Hospital systems investing directly in the company can pull adoption forward faster than pure financial rounds, creating a network effect across healthcare institutions.
• Strategic Partnerships: The startup maintains relationships with major technology companies including Google, Microsoft, Anthropic, and Nvidia, giving it access to cutting-edge AI infrastructure and models.
• Acquisition Potential: As an acquisition target, OpenEvidence could offer acquirers immediate access to doctors using its product, experience handling sensitive medical information, and a foothold in a massive healthcare market.

The timing of this round is significant. OpenEvidence's funding comes as major AI companies like OpenAI and Anthropic are making bigger pushes into healthcare. Rather than simply providing the underlying AI models that power other companies' products, these AI giants are increasingly building healthcare tools of their own. For a company like OpenAI or Anthropic, acquiring OpenEvidence would provide a shortcut to market penetration and user adoption.

What Does This Mean for the Broader AI Investment Landscape?

OpenEvidence's rapid scaling reflects a notable trend in venture capital: health-adjacent AI remains one of the few non-infrastructure AI categories still commanding mega-round-adjacent checks. While some pure AI-infrastructure valuations have drawn skepticism from investors, healthcare applications continue to attract substantial capital. In the same week as OpenEvidence's announcement, other health-focused AI and biotech companies raised significant funding, including ADARx Pharmaceuticals, which raised $535.3 million including its Nasdaq IPO pricing, and Precision Neuroscience, which raised $250 million for brain-computer interface technology.

The clustering of large health AI funding rounds suggests investor appetite for healthcare-adjacent AI remains strong. This contrasts with some skepticism around pure infrastructure plays, where valuations have faced more scrutiny. For founders and investors watching the market, the message is clear: specialized AI applications solving real problems in regulated industries like healthcare continue to attract institutional capital at scale.

OpenEvidence's valuation jump from $12 billion in January 2026 to $15 billion in September 2026 also signals confidence in the company's ability to scale and potentially become an acquisition target. The startup could be open to selling itself, which would provide access to computing resources that could become scarcer in the future if rising anti-AI sentiment curbs data center expansion, according to people familiar with the matter. However, OpenEvidence may prefer to remain independent.

As healthcare systems continue to adopt AI tools and major tech companies compete for dominance in the healthcare AI space, OpenEvidence's position as a widely-used clinical search engine gives it significant leverage in negotiations with potential acquirers or partners. The next chapter for the startup will likely involve either continued independent growth, strategic partnerships with major AI companies, or acquisition by one of the tech giants seeking to own more of the healthcare AI market.